Cargando…
Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market. The Food and Drug Administration and European Medicines Agency recently approved the alirocumab and evolocumab, subcuta...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242035/ https://www.ncbi.nlm.nih.gov/pubmed/28163543 http://dx.doi.org/10.4103/0976-500X.195906 |
_version_ | 1782496286919884800 |
---|---|
author | Mazhar, Faizan Haider, Nafis |
author_facet | Mazhar, Faizan Haider, Nafis |
author_sort | Mazhar, Faizan |
collection | PubMed |
description | The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market. The Food and Drug Administration and European Medicines Agency recently approved the alirocumab and evolocumab, subcutaneously injectable monoclonal antibody every 2 or 4 weeks against PCSK9, for the treatment of hypercholesterolemia in patients with intolerance or inadequate response to statins, especially for the secondary prevention or in the case of familial hypercholesterolemia. This decision is based on several clinical trials demonstrating that inhibitors of PCSK9 lower the low-density lipoprotein cholesterol compared to placebo while studies are underway to assess their role in secondary prevention of major cardiovascular events. |
format | Online Article Text |
id | pubmed-5242035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-52420352017-02-03 Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia Mazhar, Faizan Haider, Nafis J Pharmacol Pharmacother Molecules of Millennium The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market. The Food and Drug Administration and European Medicines Agency recently approved the alirocumab and evolocumab, subcutaneously injectable monoclonal antibody every 2 or 4 weeks against PCSK9, for the treatment of hypercholesterolemia in patients with intolerance or inadequate response to statins, especially for the secondary prevention or in the case of familial hypercholesterolemia. This decision is based on several clinical trials demonstrating that inhibitors of PCSK9 lower the low-density lipoprotein cholesterol compared to placebo while studies are underway to assess their role in secondary prevention of major cardiovascular events. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5242035/ /pubmed/28163543 http://dx.doi.org/10.4103/0976-500X.195906 Text en Copyright: © 2016 Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Molecules of Millennium Mazhar, Faizan Haider, Nafis Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia |
title | Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia |
title_full | Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia |
title_fullStr | Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia |
title_full_unstemmed | Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia |
title_short | Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia |
title_sort | proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: an emerging new therapeutic option for the treatment of dyslipidemia |
topic | Molecules of Millennium |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242035/ https://www.ncbi.nlm.nih.gov/pubmed/28163543 http://dx.doi.org/10.4103/0976-500X.195906 |
work_keys_str_mv | AT mazharfaizan proproteinconvertasesubtilisinkexintype9enzymeinhibitorsanemergingnewtherapeuticoptionforthetreatmentofdyslipidemia AT haidernafis proproteinconvertasesubtilisinkexintype9enzymeinhibitorsanemergingnewtherapeuticoptionforthetreatmentofdyslipidemia |